The subject invention provides a pharmaceutical composition comprising: an, aqueous carrier from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of and b), or at least two of the sequences in (a)(1), (a) (ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a) (i), (a) (ii) and (b) (i) through (b)(x) and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition.Linvention concerne une composition pharmaceutique comprenant : un excipient aqueux entre 0,1 mg/ml et 20 mg/ml dun sel pharmaceutiquement acceptable de : a) un peptide comprenant au moins 12 à au plus 30 acides aminés consécutifs présentant une séquence correspondant à (i) une séquence dacides aminés détectée dans une région hypervariable (CDR) dune chaîne lourde ou légère dun anticorps monoclonal humain anti-ADN 16/6 Id, ou (ii) une séquence dacides aminés détectée dans une région hypervariable (CDR) dune chaîne lourde ou légère dun anticorps monoclonal pathogène anti-ADN
